siRNA-mediated MDM2 inhibition sensitizes human lung cancer A549 cells to radiation

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1447-1452

  Guo, Wanfeng ^a,b   Ahmed, Kazi Mokim ^c   Hui, Yanpin ^a   Guo, Guozheng ^a   Li, Jian Jian ^c,d  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Beijing 307 Hospital   (China)

^c PURDUE UNIVERSITY   (United States)

^d Purdue University   (United States)

Author keywords

A549 cells; Ionizing radiation; MDM2; Radiosensitivity; siRNA

Indexed keywords

MDM2 PROTEIN, HUMAN; PROTEIN MDM2; RADIOSENSITIZING AGENT; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; DRUG ANTAGONISM; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; LUNG TUMOR; PHYSIOLOGY; RADIATION DOSE; RADIATION EXPOSURE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 34447276471     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1447     Document Type: Article

References (40)

1. Spira A and Ettinger DS: Multidisciplinary management of lung cancer. N Engl J Med 350: 379-392, 2004.
2. Komaki R, Liao Z and Milas L: Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin Oncol 31: 47-53, 2004. (Pubitemid 38241020)
3. Dy GK and Adjei AA: Novel targets for lung cancer therapy: part I. J Clin Oncol 20: 2881-2894, 2002. (Pubitemid 34651518)
4. Stassen T, Port M, Nuyken I and Abend M: Radiation-induced gene expression in MCF-7 cells. Int J Radiat Biol 79: 319-331, 2003.
5. Yin E, Nelson DO, Coleman MA, Peterson LE and Wyrobek AJ: Gene expression changes in mouse brain after exposure to low-dose ionizing radiation. Int J Radiat Biol 79: 759-775, 2003. (Pubitemid 37468143)
6. Lehnert S: Prediction of tumor response to therapy: molecular markers and the microenvironment. Apoptosis and chips: an overview of the proceedings. Radiat Res 154: 121-124, 2000.
7. Guo G, Yan-Sanders Y, Lyn-Cook BD, Wang T, Tamae D, Ogi J, Khaletskiy A, Li Z, Weydert C, Longmate JA, Huang TT, Spitz DR, Oberley LW and Li JJ: Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses. Mol Cell Biol 23: 2362-2378, 2003.
8. Xia L, Paik A and Li JJ: p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2/p14ARF. Cancer Res 64: 221-228, 2004.
9. Guo WF, Lin RX, Huang J, Zhou Z, Yang J, Guo GZ and Wang SQ: Identification of differentially expressed genes contributing to radioresistance in lung cancer cells using microarray analysis. Radiat Res 164: 27-35, 2005. (Pubitemid 40885227)
10. Perry ME: Mdm2 in the response to radiation. Mol Cancer Res 2: 9-19, 2004.
11. Iwakuma T and Lozano G: MDM2, an introduction. Mol Cancer Res 1: 993-1000, 2003.
12. Ganguli G and Wasylyk B: p53-independent functions of MDM2. Mol Cancer Res 1: 1027-1035, 2003.
13. Oliner JD, Kinzler KW, Meltzer PS, George DL and Vogelstein B: Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83, 1992.
14. Cordon-Cardo C, Latres E, Drobnjak M, Oliva MR, Pollack D, Woodruff JM, Marechal V, Chen J, Brennan MF and Levine AJ: Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54: 794-799, 1994. (Pubitemid 24068339)
15. Gorgoulis VG, Zacharatos P, Kotsinas A, Liloglou T, Kyroudi A, Veslemes M, Rassidakis A, Halazonetis TD, Field JK and Kittas C: Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol 153: 1749-1765, 1998.
16. Valassiadou KE, Stefanaki K, Tzardi M, Datseris G, Georgoulias V, Melissas J, Tsiftsis DD, Delides G and Kanavaros P: Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas. Anticancer Res 17: 2571-2576, 1997.
17. Sjostrom J, Blomqvist C, Heikkila P, Boguslawski KV, Raisanen-Sokolowski A, Bengtsson NO, Mjaaland I, Malmstrom P, Ostenstadt B, Bergh J, Wist E, Valvere V and Saksela E: Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 6: 3103-3110, 2000.
18. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K and Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001. (Pubitemid 32494397)
19. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA and Herweijer H: Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 32: 107-108, 2002.
20. Lammering G, Hewit TH, Valerie K, Lin PS, Contessa JN and Schmidt-Ullrich RK: Anti-erbB receptor strategy as a gene therapeutic intervention to improve radiotherapy in malignant human tumours. Int J Radiat Biol 79: 561-568, 2003. (Pubitemid 37311061)
21. Rosenberg SA: Gene therapy for cancer. JAMA 268: 2416-2419, 1992.
22. Hoang T, Traynor AM and Schiller JH: Novel therapies for lung cancer. Surg Oncol 11: 229-241, 2002.
23. Buolamwini JK, Addo J, Kamath S, Patil S, Mason D and Ores M: Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr Cancer Drug Targets 5: 57-68, 2005. (Pubitemid 40326247)
24. Onel K and Cordon-Cardo C: MDM2 and prognosis. Mol Cancer Res 2: 1-8, 2004.
25. Slack A and Shohet JM: MDM2 as a critical effector of the MYCN oncogene in tumorigenesis. Cell Cycle 4: 857-860, 2005. (Pubitemid 41359744)
26. McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G and Dervan PA: Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br J Cancer 71: 981-985, 1995.
27. Marchetti A, Buttitta F, Girlando S, Dalla Palma P, Pellegrini S, Fina P, Doglioni C, Bevilacqua G and Barbareschi M: mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 175: 31-38, 1995.
28. Dworakowska D, Jassem E, Jassem J, Peters B, Dziadziuszko R, Zylicz M, Jakobkiewicz-Banecka J, Kobierska-Gulida G, Szymanowska A, Skokowski J, Roessner A and Schneider-Stock R: MDM2 gene amplification: a new independent factor of adverse prognosis in non-small cell lung cancer (NSCLC). Lung Cancer 43: 285-295, 2004.
29. Steinman HA, Burstein E, Lengner C, Gosselin J, Pihan G, Duckett CS and Jones SN: An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 279: 4877-4886, 2004.
30. Momand J, Jung D, Wilczynski S and Niland J: The MDM2 gene amplification database. Nucleic Acids Res 26: 3453-3459, 1998.
31. Chene P: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer 3: 102-109, 2003.
32. Mu Z, Hachem P, Agrawal S and Pollack A: Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. Int J Radiat Oncol Biol Phys 58: 336-343, 2004. (Pubitemid 38142457)
33. Sato N, Mizumoto K, Maehara N, Kusumoto M, Nishio S, Urashima T, Ogawa T and Tanaka M: Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1. Anticancer Res 20: 837-842, 2000.
34. Shi Y: Mammalian RNAi for the masses. Trends Genet 19: 9-12, 2003.
35. Tan FL and Yin JQ: RNAi, a new therapeutic strategy against viral infection. Cell Res 14: 460-466, 2004. (Pubitemid 43231790)
36. Collis SJ, Swartz MJ, Nelson WG and De Weese TL: Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 63: 1550-1554, 2003.
37. Wu H, Hait WN and Yang JM: Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 63: 1515-1519, 2003. (Pubitemid 36373637)
38. Guo GZ, Sasai K, Oya N, Takagi T, Shibuya K and Hiraoka M: Simultaneous evaluation of radiation-induced apoptosis and micronuclei in five cell lines. Int J Radiat Biol 73: 297-302, 1998. (Pubitemid 28160916)
39. Guo GZ, Sasai K, Oya N, Shibata T, Shibuya K and Hiraoka MA: Significant correlation between clonogenic radiosensitivity and the simultaneous assessment of micronucleus and apoptotic cell frequencies. Int J Radiat Biol 75: 857-864, 1999. (Pubitemid 29336562)
40. Yu Y, Sun P, Sun LC, Liu GY, Chen GH, Shang LH, Wu HB, Hu J, Li Y, Mao YL, Sui GJ and Sun XW: Downregulation of MDM2 expression by RNAi inhibits LoVo human colorectal adenocarcinoma cells growth and the treatment of LoVo cells with mdm2siRNA3 enhances the sensitivity to cisplatin. Biochem Biophys Res Commun 339: 71-78, 2006.